Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a hold rating to a strong-buy rating in a research report report published on Saturday morning.

Other equities research analysts have also issued research reports about the stock. Piper Sandler reduced their target price on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating for the company in a research report on Friday. Bank of America restated an “underperform” rating and set a $20.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, June 29th. Jefferies Financial Group reaffirmed a “hold” rating and set a $22.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, April 21st. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, July 8th. Finally, Zacks Research upgraded shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 21st. Six research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $22.00.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ:AMPH opened at $20.31 on Friday. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.40 and a quick ratio of 1.71. The business’s 50 day moving average price is $19.70 and its 200-day moving average price is $21.32. The firm has a market capitalization of $863.99 million, a PE ratio of 12.02, a P/E/G ratio of 4.39 and a beta of 0.89. Amphastar Pharmaceuticals has a 1 year low of $16.65 and a 1 year high of $31.26.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.62 by $0.29. The firm had revenue of $183.90 million during the quarter, compared to the consensus estimate of $179.92 million. Amphastar Pharmaceuticals had a return on equity of 14.98% and a net margin of 10.76%. As a group, equities research analysts expect that Amphastar Pharmaceuticals will post 2.25 earnings per share for the current fiscal year.

Institutional Trading of Amphastar Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of AMPH. Rice Hall James & Associates LLC grew its holdings in shares of Amphastar Pharmaceuticals by 54.6% during the 1st quarter. Rice Hall James & Associates LLC now owns 187,348 shares of the company’s stock worth $3,670,000 after purchasing an additional 66,172 shares during the period. Denali Advisors LLC raised its holdings in Amphastar Pharmaceuticals by 56.9% in the 4th quarter. Denali Advisors LLC now owns 211,765 shares of the company’s stock valued at $5,671,000 after buying an additional 76,765 shares during the period. Pacer Advisors Inc. raised its holdings in Amphastar Pharmaceuticals by 47.1% in the 1st quarter. Pacer Advisors Inc. now owns 261,483 shares of the company’s stock valued at $5,122,000 after buying an additional 83,739 shares during the period. Dimensional Fund Advisors LP lifted its position in Amphastar Pharmaceuticals by 12.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock valued at $39,726,000 after buying an additional 228,262 shares during the last quarter. Finally, Cibc World Market Inc. acquired a new position in Amphastar Pharmaceuticals in the fourth quarter valued at about $1,666,000. 65.09% of the stock is owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.